Avalo Therapeutics, Inc. (AVTX)
AVTX Stock Price Chart
Explore Avalo Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze AVTX price movements and trends.
AVTX Company Profile
Discover essential business fundamentals and corporate details for Avalo Therapeutics, Inc. (AVTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
14 Oct 2015
Employees
23.00
Website
https://www.avalotx.comCEO
Garry A. Neil
Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
AVTX Financial Timeline
Browse a chronological timeline of Avalo Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 Mar 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$1.67.
Earnings released on 7 Aug 2025
EPS came in at -$1.92 falling short of the estimated -$1.43 by -34.27%.
Earnings released on 12 May 2025
EPS came in at -$1.25 falling short of the estimated -$1.07 by -16.82%.
Earnings released on 20 Mar 2025
EPS came in at -$7.95 falling short of the estimated -$0.39 by -1.94K%, while revenue for the quarter reached $192.00K .
Earnings released on 7 Nov 2024
EPS came in at -$2.83 falling short of the estimated -$1.19 by -137.82%, while revenue for the quarter reached $249.00K .
Earnings released on 12 Aug 2024
EPS came in at -$14.07 falling short of the estimated -$6.70 by -110.00%.
Earnings released on 13 May 2024
EPS came in at -$5.98 falling short of the estimated -$1.18 by -406.78%.
Earnings released on 29 Mar 2024
EPS came in at -$116.21 falling short of the estimated -$4.80 by -2.32K%, while revenue for the quarter reached $571.00K , beating expectations by +90.33%.
Stock split effective on 29 Dec 2023
Shares were split 1 : 240 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Nov 2023
EPS came in at -$26.19 surpassing the estimated -$261.90 by +90.00%, while revenue for the quarter reached $236.00K , missing expectations by -21.33%.
Earnings released on 3 Aug 2023
EPS came in at -$140.48 surpassing the estimated -$214.29 by +34.44%, while revenue for the quarter reached $643.00K , beating expectations by +28.60%.
Earnings released on 4 May 2023
EPS came in at -$202.38 surpassing the estimated -$230.95 by +12.37%, while revenue for the quarter reached $475.00K , missing expectations by -52.50%.
Earnings released on 29 Mar 2023
EPS came in at -$247.62 falling short of the estimated -$123.81 by -100.00%, while revenue for the quarter reached $896.00K , missing expectations by -75.18%.
Earnings released on 7 Nov 2022
EPS came in at $80.95 surpassing the estimated -$245.24 by +133.01%, while revenue for the quarter reached $14.95M , beating expectations by +1.09K%.
Earnings released on 4 Aug 2022
EPS came in at -$328.57 surpassing the estimated -$428.57 by +23.33%, while revenue for the quarter reached $1.03M , missing expectations by -12.94%.
Stock split effective on 8 Jul 2022
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 5 May 2022
EPS came in at -$571.66 falling short of the estimated -$400.16 by -42.86%, while revenue for the quarter reached $1.17M , beating expectations by +81.72%.
Earnings released on 2 Mar 2022
EPS came in at -$1.92 falling short of the estimated -$1.90 by -1.05%, while revenue for the quarter reached $219.00K , missing expectations by -78.49%.
Earnings released on 9 Nov 2021
EPS came in at -$485.91 surpassing the estimated -$543.07 by +10.53%, while revenue for the quarter reached $1.35M , beating expectations by +66.67%.
Earnings released on 2 Aug 2021
EPS came in at -$2.16 falling short of the estimated -$2.04 by -5.88%, while revenue for the quarter reached $3.36M , meeting expectations.
Earnings released on 13 May 2021
EPS came in at -$3.84 falling short of the estimated -$2.32 by -65.52%, while revenue for the quarter reached $473.00K , beating expectations by +27.95%.
Earnings released on 8 Mar 2021
EPS came in at -$2.16 falling short of the estimated -$1.80 by -20.00%, while revenue for the quarter reached $1.50M , beating expectations by +49.62%.
Earnings released on 9 Nov 2020
EPS came in at -$2.04 falling short of the estimated -$1.14 by -78.95%, while revenue for the quarter reached $1.11M , beating expectations by +7.74%.
AVTX Stock Performance
Access detailed AVTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.